Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

Eli Lilly (NYSE:LLY) shares rose 6% in the premarket on Thursday after the drugmaker beat Wall Street expectations with its ...

Now, let’s talk about the real contenders, okay. Let’s start with Eli Lilly, one I always said was going to get to trillion ...

Importantly, BGE-102 is an oral candidate. The current leaders in the anti-obesity market are administered via subcutaneous ...